These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
318 related items for PubMed ID: 30617554
1. Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. Bashir U, Tree A, Mayer E, Levine D, Parker C, Dearnaley D, Oyen WJG. Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):901-907. PubMed ID: 30617554 [Abstract] [Full Text] [Related]
3. 3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. Emmett L, Tang R, Nandurkar R, Hruby G, Roach P, Watts JA, Cusick T, Kneebone A, Ho B, Chan L, van Leeuwen PJ, Scheltema MJ, Nguyen A, Yin C, Scott A, Tang C, McCarthy M, Fullard K, Roberts M, Francis R, Stricker P. J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727 [Abstract] [Full Text] [Related]
7. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Metser U, Chua S, Ho B, Punwani S, Johnston E, Pouliot F, Tau N, Hawsawy A, Anconina R, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Pond G, Scott AM, Tunariu N, Sidhu H, Emmett L. J Nucl Med; 2019 Sep; 60(9):1253-1258. PubMed ID: 30902875 [Abstract] [Full Text] [Related]
8. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469 [Abstract] [Full Text] [Related]
11. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U. Radiat Oncol; 2017 Nov 10; 12(1):176. PubMed ID: 29126446 [Abstract] [Full Text] [Related]
12. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C. Radiat Oncol; 2018 Mar 02; 13(1):37. PubMed ID: 29499730 [Abstract] [Full Text] [Related]
14. The use of 68 Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T. BJU Int; 2016 Oct 02; 118 Suppl 3():49-55. PubMed ID: 27659411 [Abstract] [Full Text] [Related]
19. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S. Eur J Nucl Med Mol Imaging; 2019 Jan 02; 46(1):31-39. PubMed ID: 30350010 [Abstract] [Full Text] [Related]
20. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. Rogowski P, Trapp C, von Bestenbostel R, Eze C, Ganswindt U, Li M, Unterrainer M, Zacherl MJ, Ilhan H, Beyer L, Kretschmer A, Bartenstein P, Stief C, Belka C, Schmidt-Hegemann NS. Eur J Nucl Med Mol Imaging; 2022 Mar 02; 49(4):1417-1428. PubMed ID: 34628521 [Abstract] [Full Text] [Related] Page: [Next] [New Search]